The primary goal of the Pathology Core (PC) is to provide investigators of this program project with a centralized, comprehensive facility for human tissue-based research. The resource will enhance the infrastructure, optimize tissue use and facilitate rapid advances in specific projects by 1) providing appropriate human tissues and associated data in an equitable and ethical manner, 2) providing professional expertise in histo- and molecular pathology, and 3) performing tissue based experimentation. The PC also implements stringent quality control standards to ensure that consistent, valid services are provided to investigators using the shared resource. This centralized core is the most efficient and cost-effective means to provide these necessary research components to multiple investigators in this program by eliminating duplication of effort and equipment, and centralizing quality control. The resource will also be a logistic, technological and intellectual bridge between basic and clinical investigators.
The specific aims of the core are: 1) To provide pathology expertise at all stages of project development and experimentation using human tissue. 2) To procure well-characterized neoplastic and nonneoplastic human tissue required for individual projects without compromise of patient care. 3) To record and maintain pertinent histopathology data in a secure, relational database designed for efficient data transfer and analyses of clinical, genetic and molecular correlations. 4) To consistently process, store and distribute tissue samples and biomaterials according to individual research of investigators of this program project. 5) To provide routine histologic techniques, microdissection for tissue component purification, and technical assistance in tissue-based experimentation. 6) To provide immunohistochemistry services including antibody characterization and optimization for immunohistochemistry.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA106450-05
Application #
7847715
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
5
Fiscal Year
2009
Total Cost
$165,527
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Kushner, Brian H; Ostrovnaya, Irina; Cheung, Irene Y et al. (2016) Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget 7:4155-66
Cheung, Nai-Kong V; Cheung, Irene Y; Kramer, Kim et al. (2014) Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer 135:2199-205
Dobrenkov, Konstantin; Cheung, Nai-Kong V (2014) GD2-targeted immunotherapy and radioimmunotherapy. Semin Oncol 41:589-612
Kushner, Brian H; Modak, Shakeel; Kramer, Kim et al. (2014) Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era. Cancer 120:2050-9
O'Neill, Alison; Shah, Nilay; Zitomersky, Naamah et al. (2013) Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature. Sarcoma 2013:450478
Kushner, Brian H; Modak, Shakeel; Basu, Ellen M et al. (2013) Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody. Cancer 119:2789-95
Ahn, Eun Hyun; Mercado, Gabriela E; LaƩ, Marick et al. (2013) Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Oncol Rep 30:968-78
Shukla, Neerav; Ameur, Nabahet; Yilmaz, Ismail et al. (2012) Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res 18:748-57
Wang, Lu; Motoi, Toru; Khanin, Raya et al. (2012) Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer 51:127-39
Cheung, Nai-Kong V; Cheung, Irene Y; Kushner, Brian H et al. (2012) Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol 30:3264-70

Showing the most recent 10 out of 47 publications